EZH2 and hepatocellular carcinoma: By establishing a CRGs-based prognosis model with the five hallmark genes (G6PD, PRR11, KIF20A, EZH2, and CDCA8), it brought prospective targets for determining the therapeutic efficacy of immunotherapy and targeted therapy, and accurately predicting the survival of HCC.